Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Graeme C Young

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
British Journal of Clinical Pharmacology|July 22, 2014
Human absorption, distribution, metabolism and excretion properties of drug molecules: a plethora of approachesClaire Beaumont, Graeme C Young, Tom Cavalier, et al.
The AAPS Journal|February 7, 2014
New frontiers-accelerator mass spectrometry (AMS): Recommendation for best practices and harmonization from Global Bioanalysis Consortium Harmonization TeamGraeme C Young, Mark Seymour, Stephen R Dueker, et al.
Alternatives to Laboratory Animals : ATLA|January 19, 2019
Phase 0, including microdosing approaches: Applying the Three Rs and increasing the efficiency of human drug developmentTal Burt, Le Thuy Vuong, Elizabeth Baker, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 24, 2022
Investigation of Clinical Absorption, Distribution, Metabolism, and Excretion and Pharmacokinetics of the HIV-1 Maturation Inhibitor GSK3640254 Using an Intravenous Microtracer Combined with EnteroTracker for Biliary SamplingBo Wen, Ying Zhang, Graeme C Young, et al.
British Journal of Clinical Pharmacology|March 11, 2014
Concomitant oral and intravenous pharmacokinetics of trametinib, a MEK inhibitor, in subjects with solid tumoursCathrine Leonowens, Carolyn Pendry, John Bauman, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 1, 2014
Disposition and metabolism of darapladib, a lipoprotein-associated phospholipase A2 inhibitor, in humansMehul Dave, Mike Nash, Graeme C Young, et al.
Journal of Clinical Pharmacology|July 13, 2013
Concomitant oral and intravenous pharmacokinetics of dabrafenib, a BRAF inhibitor, in patients with BRAF V600 mutation-positive solid tumorsCathrine L Denton, Elisabeth Minthorn, Stanley W Carson, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 9, 2012
Metabolism and disposition of vilanterol, a long-acting β(2)-adrenoceptor agonist for inhalation use in humansAndrew W Harrell, Sarah K Siederer, Jo Bal, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|February 27, 2013
Disposition and metabolism of GSK2251052 in humans: a novel boron-containing antibioticGary D Bowers, David Tenero, Parul Patel, et al.
Antimicrobial Agents and Chemotherapy|February 20, 2020
A Novel Inhaled Dry-Powder Formulation of Ribavirin Allows for Efficient Lung Delivery in Healthy Participants and Those with Chronic Obstructive Pulmonary Disease in a Phase 1 StudyEtienne F Dumont, Amanda J Oliver, Chris Ioannou, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
British Journal of Clinical Pharmacology|July 22, 2014
Human absorption, distribution, metabolism and excretion properties of drug molecules: a plethora of approachesClaire Beaumont, Graeme C Young, Tom Cavalier, et al.
The AAPS Journal|February 7, 2014
New frontiers-accelerator mass spectrometry (AMS): Recommendation for best practices and harmonization from Global Bioanalysis Consortium Harmonization TeamGraeme C Young, Mark Seymour, Stephen R Dueker, et al.
Alternatives to Laboratory Animals : ATLA|January 19, 2019
Phase 0, including microdosing approaches: Applying the Three Rs and increasing the efficiency of human drug developmentTal Burt, Le Thuy Vuong, Elizabeth Baker, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 24, 2022
Investigation of Clinical Absorption, Distribution, Metabolism, and Excretion and Pharmacokinetics of the HIV-1 Maturation Inhibitor GSK3640254 Using an Intravenous Microtracer Combined with EnteroTracker for Biliary SamplingBo Wen, Ying Zhang, Graeme C Young, et al.
British Journal of Clinical Pharmacology|March 11, 2014
Concomitant oral and intravenous pharmacokinetics of trametinib, a MEK inhibitor, in subjects with solid tumoursCathrine Leonowens, Carolyn Pendry, John Bauman, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 1, 2014
Disposition and metabolism of darapladib, a lipoprotein-associated phospholipase A2 inhibitor, in humansMehul Dave, Mike Nash, Graeme C Young, et al.
Journal of Clinical Pharmacology|July 13, 2013
Concomitant oral and intravenous pharmacokinetics of dabrafenib, a BRAF inhibitor, in patients with BRAF V600 mutation-positive solid tumorsCathrine L Denton, Elisabeth Minthorn, Stanley W Carson, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 9, 2012
Metabolism and disposition of vilanterol, a long-acting β(2)-adrenoceptor agonist for inhalation use in humansAndrew W Harrell, Sarah K Siederer, Jo Bal, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|February 27, 2013
Disposition and metabolism of GSK2251052 in humans: a novel boron-containing antibioticGary D Bowers, David Tenero, Parul Patel, et al.
Antimicrobial Agents and Chemotherapy|February 20, 2020
A Novel Inhaled Dry-Powder Formulation of Ribavirin Allows for Efficient Lung Delivery in Healthy Participants and Those with Chronic Obstructive Pulmonary Disease in a Phase 1 StudyEtienne F Dumont, Amanda J Oliver, Chris Ioannou, et al.
Pageof 2